EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Harnessing probiotic-metformin synergy: targeting the gut-microbiota metabolism axis to ameliorate polycystic ovary syndrome

Wanqiu Yang, Lin Yin, Qingling Xie, Moyao Tan, Yunzhu Liu, Jili Xu, Jie Wu

Frontiers in Nutrition · 15.01.2026 · 12

DOI: 10.3389/fnut.2025.1699600 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Nutrition, online erschienen am 15.01.2026. Verfasst von Wanqiu Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus (T2DM) are interrelated through insulin resistance (IR) and gut microbiota dysbiosis. This review evaluates the synergistic efficacy and mechanisms of a combined probiotic and metformin regimen in the management of PCOS, with a specific focus on the gut-ovary-metabolism axis.

Methods

A systematic literature search was conducted following PROSPERO (ID: CRD420251143914) registration across PubMed, EMBASE, Web of Science, the China National Knowledge Infrastructure (CNKI), the Wanfang Database, and the VIP Database, prioritizing randomized controlled trials and retrospective studies.

Results

The combination therapy suggests improved outcomes compared to metformin monotherapy, yielding significant improvements in metabolic, hormonal, and reproductive function. Crucially, probiotics alleviated metformin-induced gastrointestinal adverse effects, thereby enhancing treatment adherence. The proposed underlying mechanisms involve a synergistic restoration of gut microbial homeostasis, increased production of short-chain fatty acids, reinforcement of the intestinal barrier, and potentiated activation of the AMP-Activated Protein Kinase (AMPK) pathway.

Conclusion

As an adjunct supplement to metformin, probiotics represent a novel, evidence-supported therapeutic strategy for PCOS. This approach offers enhanced efficacy and tolerability, with potential implications for a broader spectrum of metabolic disorders including T2DM; however, given the current paucity of related studies, conclusions should be drawn cautiously. Systematic review registration [ https://www.crd.york.ac.uk/prospero/ ], identifier [CRD420251143914].

Schlagwörter

Stichwörter der Autor:innen

AMPKgut microbiotainsulin resistancemetforminpolycystic ovary syndromeprobioticsshort-chain fatty acids

Autor:innen und Institutionen

  • Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
  • Yibin Second Hospital of Traditional Chinese Medicine, Yibin, Sichuan, China.

Zitieren

APA

Yang, W., Yin, L., Xie, Q., Tan, M., Liu, Y., Xu, J., & Wu, J. (2026). Harnessing probiotic-metformin synergy: targeting the gut-microbiota metabolism axis to ameliorate polycystic ovary syndrome. Frontiers in Nutrition, 12. https://doi.org/10.3389/fnut.2025.1699600

Vancouver

Yang W, Yin L, Xie Q, Tan M, Liu Y, Xu J, et al. Harnessing probiotic-metformin synergy: targeting the gut-microbiota metabolism axis to ameliorate polycystic ovary syndrome. Frontiers in Nutrition. 2026;12. doi:10.3389/fnut.2025.1699600

BibTeX
@article{Yang2026,
  author = {Yang, Wanqiu and Yin, Lin and Xie, Qingling and Tan, Moyao and Liu, Yunzhu and Xu, Jili and Wu, Jie},
  title = {Harnessing probiotic-metformin synergy: targeting the gut-microbiota metabolism axis to ameliorate polycystic ovary syndrome},
  journal = {Frontiers in Nutrition},
  year = {2026},
  volume = {12},
  doi = {10.3389/fnut.2025.1699600}
}
Kostenlos starten →